Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kiersten Stead
AddedMar 31, 2024
UpdatedMay 31, 2026
Kiersten Stead

Kiersten Stead

Co-Founder, Dcvc Bio

CrunchbaseLinkedIn

Kiersten Stead's Career

Dcvc Bio
Dcvc Bio

Palo Alto, CA, US

Co-Founder
X-37
X-37

San Francisco, CA, US

Board Member· Board
Novome Biotechnologies
Novome Biotechnologies

South San Francisco, CA, US

Board Member· Board
MycoWorks
MycoWorks

Emeryville, CA, US

Board Member· Board
Pairwise Plants
Pairwise Plants

Durham, NC, US

Co-Founder
Plexium
Plexium

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kiersten Stead's Career

Dcvc Bio
Dcvc Bio
Investment FirmInvestment Firm142018Palo Alto, CA, US
Co-Founder

Recent news

Sources: Naveen Rao’s new AI hardware startup targets $5B valuation with backing from a16zTechCrunch · 2025
TED leader’s $300M ‘valley of death’ fund might be just what later-stage climate tech needsTechCrunch · 2025
Rocket Lab backer Outset raises $25M to fund New Zealand’s deep tech moonshotsTechCrunch · 2025

Leadership at Dcvc Bio

John HamerJohn HamerCo-Founder
Matthew OckoMatthew OckoCo-Founder
Zachary BogueZachary BogueCo-Founder
Anna FokinaAnna FokinaCo-Founder

Similar to Dcvc Bio

DcvcDcvcSan Francisco, CA, USest. 2011DcvcSan Francisco, CA, US · est. 2011

DCVC: A deep tech investment firm with 20+ years of backing industry-changing entrepreneurs.

Investment Firm91
DCMDCMMenlo Park, CA, USest. 1996DCMMenlo Park, CA, US · est. 1996

California-based financial services firm, DCM Ventures, partners with entrepreneurs to build impactful global tech companies.

Investment Firm275
Bioluminescence VenturesBioluminescence VenturesSan Francisco, CA, USest. 2022Bioluminescence VenturesSan Francisco, CA, US · est. 2022

US-based Bioluminescence, a biotech venture firm, invests in transformative science for next-gen medicines, focusing on breakthrough biology, drug discovery, and computational platforms.

Investment Firm7
DVCDVCSan Francisco, CA, USest. 2020DVCSan Francisco, CA, US · est. 2020

DVC: A global venture investor syndicate, funding companies from pre-seed to pre-IPO.

Investment Firm125
X-37
X-37
Series A$14.5M52018San Francisco, CA, US
Board Member· Board

Leadership at X-37

Abraham HeifetsAbraham HeifetsFounder
David CollierDavid CollierCEO
David CollierDavid CollierBoard Member

Similar to X-37

DeepCureDeepCureBoston, MA, USDrug Discoveryest. 2018DeepCureBoston, MA, US · est. 2018

DeepCure: Accelerating affordable AI-powered drug discovery for better, faster results.

Series A · $40M39
Phronesis Artificial IntelligencePhronesis Artificial IntelligenceDaphne, AL, USPharmaceutical Softwareest. 2020Phronesis Artificial IntelligenceDaphne, AL, US · est. 2020

Phronesis AI develops advanced pharmaceutical software for autonomous drug discovery and disease targeting.

Angel · $300k7
Atomic AIAtomic AISouth San Francisco, CA, USDrug Discoveryest. 2021Atomic AISouth San Francisco, CA, US · est. 2021

Atomic AI: Pioneering molecule and medicine design through AI and structural biology fusion.

Series A · $42M38
CognaisentCognaisentCambridge, MA, USDrug Discoveryest. 2018CognaisentCambridge, MA, US · est. 2018

Cognaisent: Revolutionizing AI with machine learning for drug discovery and molecular analysis.

Angel · $147k7
Novome Biotechnologies
Novome Biotechnologies

South San Francisco, CA, US

Board Member· Board
MycoWorks
MycoWorks

Emeryville, CA, US

Board Member· Board
Pairwise Plants
Pairwise Plants
Series B$115M752017Durham, NC, US
Co-Founder

Recent news

Sequoia nears first Asia-Pacific deal since regional splitTechCrunch · 2024

Leadership at Pairwise Plants

J. Keith JoungJ. Keith JoungCo-Founder
Tom AdamsTom AdamsCEO
Michelle GloecklerMichelle GloecklerBoard Member

Similar to Pairwise Plants

Plant Pathways CompanyPlant Pathways CompanySt. Louis Park, MN, USPlant Varieties, Steviaest. 2019Plant Pathways CompanySt. Louis Park, MN, US · est. 2019

Plant Pathways Co.: Innovating health-focused food and medicinal plant varieties.

Series A · $4M30
Inari AgricultureInari AgricultureCambridge, MA, USPlant Varietiesest. 2016Inari AgricultureCambridge, MA, US · est. 2016

Inari, founded in 2016, uses predictive design to create high-performing plant varieties for sustainable agriculture.

Series F · $609M465
PlastomicsPlastomicsSt. Louis, MO, USCrop Enhancementest. 2017PlastomicsSt. Louis, MO, US · est. 2017

Plastomics Inc., a US biotech startup, enhances crop performance through chloroplast genetic engineering.

Series A · $9.4M29
BayspairBayspairMountain View, CA, USGenome Editingest. 2022BayspairMountain View, CA, US · est. 2022

Bayspair Inc.: A leading biotech startup specializing in flexible genome editing for agriculture and therapeutics.

Seed · $3.5M5
Plexium
Plexium

San Diego, CA, US

Board Member· Board

Kiersten Stead's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Kiersten Stead

Shelley AmsterShelley AmsterBoard Member · NephrogenKevin LindquistKevin LindquistCo-Founder · DecisionsMichael SteffanMichael SteffanCo-Founder · BidMoniBen KubicBen KubicCo-Founder · ProperlyAndras KindlerAndras KindlerCo-Founder · ReadyKyle LamKyle LamFounder · Big Bloom Investment